Calvin Roberts - Alimera Sciences Independent Director
| ALIM Stock | USD 3.59 0.05 1.41% |
Director
Dr. Calvin W. Roberts, M.D., is no longer an Independent Director of Alimera Sciences, Inc., June 2019. Dr. Roberts currently serves as an Executive Vice President and Chief Medical Officer of Bausch Lomb. Since 1982, Dr. Roberts has served as a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University. From 1989 to 2011, Dr. Roberts also served as a consultant to Allergan, Inc., Johnson Johnson and Novartis. Dr. Roberts holds an A.B. from Princeton University and an M.D. from the College of Physicians and Surgeons of Columbia University since 2003.
| Age | 64 |
| Tenure | 21 years |
| Professional Marks | Ph.D |
| Address | 6310 Town Square, Alpharetta, GA, United States, 30005 |
| Phone | 678 990 5740 |
| Web | https://alimerasciences.com |
Alimera Sciences Management Efficiency
The company has return on total asset (ROA) of (0.0123) % which means that it has lost $0.0123 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5876) %, meaning that it created substantial loss on money invested by shareholders. Alimera Sciences' management efficiency ratios could be used to measure how well Alimera Sciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Alimera Sciences' Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Paul Mitchell | Alkermes Plc | 64 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Robert Breyer | Alkermes Plc | 73 | |
| Grainne Troute | Evotec SE ADR | N/A | |
| Floyd Bloom | Alkermes Plc | 80 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| Anthony Quirk | Evotec SE ADR | N/A | |
| David Anstice | Alkermes Plc | 69 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
| Hamish Stevens | Evotec SE ADR | N/A | |
| Nancy Wysenski | Alkermes Plc | 60 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Lynda Reid | Evotec SE ADR | N/A | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| Norah Barlow | Evotec SE ADR | N/A | |
Management Performance
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.0123 |
Alimera Sciences Leadership Team
Elected by the shareholders, the Alimera Sciences' board of directors comprises two types of representatives: Alimera Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alimera. The board's role is to monitor Alimera Sciences' management team and ensure that shareholders' interests are well served. Alimera Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alimera Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Snisarenko, Director | ||
| Christopher Visick, General VP | ||
| Todd Wood, President Operations | ||
| James Largent, Independent Director | ||
| Peter Pizzo, Independent Director | ||
| Calvin Roberts, Independent Director | ||
| Samer Kaba, Chief Medical Officer | ||
| Mary Szela, Director | ||
| Phil Jones, CFO | ||
| Elliot CPA, CFO Treasurer | ||
| David Burke, Vice President | ||
| Philip Ashman, Sr. VP and European Managing Director | ||
| Jason Werner, Chief Officer | ||
| David Holland, Co-Founder and Sr. VP of Sales and Marketing | ||
| Garheng Kong, Independent Director | ||
| Kenneth Green, Chief Scientific Officer and Sr. VP | ||
| Richard Eiswirth, Pres and CFO | ||
| Brian Halak, Independent Director | ||
| Daniel Myers, President CEO, Director | ||
| Charles Myers, NonEx Consultant | ||
| Mark Brooks, Independent Director | ||
| Rich Cockrell, President | ||
| David MD, Chief Specialist |
Alimera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alimera Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.0123 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 230.2 M | ||||
| Shares Outstanding | 52.35 M | ||||
| Shares Owned By Insiders | 8.75 % | ||||
| Shares Owned By Institutions | 91.95 % | ||||
| Number Of Shares Shorted | 108.76 K | ||||
| Price To Earning | 1.65 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alimera Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alimera Sciences' short interest history, or implied volatility extrapolated from Alimera Sciences options trading.
Pair Trading with Alimera Sciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alimera Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alimera Sciences will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Alimera Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alimera Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alimera Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alimera Sciences to buy it.
The correlation of Alimera Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alimera Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alimera Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alimera Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alimera Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Alimera Stock analysis
When running Alimera Sciences' price analysis, check to measure Alimera Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alimera Sciences is operating at the current time. Most of Alimera Sciences' value examination focuses on studying past and present price action to predict the probability of Alimera Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alimera Sciences' price. Additionally, you may evaluate how the addition of Alimera Sciences to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Alimera Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alimera Sciences. If investors know Alimera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alimera Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.84) | Revenue Per Share 3.159 | Quarterly Revenue Growth 0.875 | Return On Assets (0.01) | Return On Equity (1.59) |
The market value of Alimera Sciences is measured differently than its book value, which is the value of Alimera that is recorded on the company's balance sheet. Investors also form their own opinion of Alimera Sciences' value that differs from its market value or its book value, called intrinsic value, which is Alimera Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alimera Sciences' market value can be influenced by many factors that don't directly affect Alimera Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alimera Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alimera Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alimera Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.